[リファキシミンとSaccharomyces boulardiiの組み合わせによる治療の有効性に関する研究 CNCM I-745 陽子ポンプ阻害剤の長期使用に関連した小腸細菌過剰増殖の患者]
I V Maev1, D N Andreev1, R I Shaburov1,2
1Russian University of Medicine.
Terapevticheskii arkhiv
|August 30, 2025
まとめ
リファキシミンとSaccharomyces boulardiiを併用した治療は,リファキシミン単独投与と比較して小腸内細菌過剰増殖 (SIBO) のアウトカムを有意に改善しました. このアプローチは,陽子ポンプ阻害剤の使用に関連したSIBOのより効果的な治療法を提供します.
科学分野:
- 胃腸内科
- 微生物学
- 薬理学について
背景:
- プロトンポンプ阻害剤 (PPI) は小腸細菌過剰増殖 (SIBO) と頻繁に関連しています.
- SIBOは重要な胃腸症状と生活の質の低下につながる可能性があります.
- PPIに関連したSIBOの効果的な管理戦略は極めて重要です.
研究 の 目的:
- リファキシミン併用療法 (リファキシミン + サッカロマイセス・ブラーディ CNCM I-745) とリファキシミン単独療法による有効性を比較する.
- PPIの長期治療を受けている患者におけるSIBOの根絶率を評価する.
- 症状の重度と生活の質への影響を評価する.
主な方法:
- PPIの長期治療を受け,SIBOが確認された108人の患者を対象とした前向きな比較試験です.
- 患者はランダムにリファキシミン単独またはリファキシミンとSaccharomyces boulardii CNCM I-745を7日間投与された.
- SIBO診断と症状/QoL評価は,乳糖HMBT,7x7アンケート,SF-36調査を用いて行われました.
主要な成果:
- リファキシミン単独療法 (58. 5%) と比較して,SIBOの根絶は併用療法群 (78. 2%) で高かった (p=0. 038).
- 腹の有意な解消は,併用グループでのみ観察された (p=0. 033).
- 併用群では,症状の全体的な重度が有意に改善した (p=0. 0010).
結論:
- リファキシミンとSaccharomyces boulardii CNCM I-745を併用した治療は,PPIに関連したSIBOに対するリファキシミン単独治療よりも効果的です.
- この組み合わせは,SIBOの根絶,症状の緩和,生活の質の改善を促進します.
- この発見は,Saccharomyces boulardiiをPPI使用者のSIBO管理における補助療法として使用することを支持する.
関連する概念動画
Drugs for Treatment of Constipation-Predominant IBS
326
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
326
Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
395
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
395
Combined Effects of Drugs: Synergism
4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.7K
Peptic Ulcer Disease IV: Management
145
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
145


